Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease
Reason given: Unexpected closure of study components -- the digital intervention (CBT-I) was no longer accessible, and alternatives were not feasible.
Key facts
- Where
- San Francisco, United StatesSee the site
Where in United States
- UCSFSan Francisco, United StatesNo longer taking part
Trial details
- Who runs it
- University of California, San Francisco
- Trial code
- NCT03256539
- Record updated
- 14 November 2025
- Original description
This study aimed to pilot test a non-pharmacological (behavioral) treatment program targeting improved cognition through improving 24-h sleep-wake cycle in people with mild cognitive impairment (MCI) or mild Alzheimer's disease. A treatment program incorporating bright light therapy and a modified cognitive behavioral therapy for insomnia will be developed to address 24-hour patterns of sleep. We will then pilot test its feasibility and explore its preliminary effects on improving sleep/napping and cognition in patients with MCI or mild Alzheimer's disease.Read full original descriptionShow less
This study aimed to pilot test a non-pharmacological (behavioral) treatment program targeting improved cognition through improving 24-h sleep-wake cycle in people with mild cognitive impairment (MCI) or mild Alzheimer's disease. A treatment program incorporating bright light therapy and a modified cognitive behavioral therapy for insomnia will be developed to address 24-hour patterns of sleep. We will then pilot test its feasibility and explore its preliminary effects on improving sleep/napping and cognition in patients with MCI or mild Alzheimer's disease.
Inclusion: ≥65 years old; Memory complaints verified by an informant; Clinical diagnosis of mild cognitive impairment (MCI) or mild Alzheimer's Disease; General cognitive performance sufficiently persevered such that a diagnosis of Alzheimer's disease cannot be made by the site physician; No evidence (CT or MRI scans within 12 months prior to screening) of infection, infarction, or other focal lesions and no clinical symptoms suggestive of intervening neurological disease; Adequate visual and auditory acuity to allow neuropsychological testing; Meets International Classification of Sleep Disorders-2nd edition (ICSD-2) criteria for insomnia or circadian rhythm disorders, or shows actigraphy evidence of sleep disturbances and excessive napping.
Exclusion: Any major neurologic disease other than suspected incipient Alzheimer's disease, such as Parkinson's disease, multi-infarct dementia, multiple sclerosis, seizure disorder, Huntington's disease, brain tumor or history of significant head trauma; Any comorbid psychiatric conditions or severe personality disorder within the past 2 years (by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition), such as major depression, bipolar disorder, schizophrenia and other psychotic features; Any uncontrolled medical conditions or systemic illness that might lead to difficulty complying with the study protocol; History of alcohol or substance abuse within the past 2 years; Any inadequately treated primary or secondary sleep disorder (due to medical conditions) that might confound the association.